Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists

References

• Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138(6):1388–1400. doi:10.1002/ijc.2989426488767
   PubMed Web of Science ®Google Scholar
• Robert Koch-Institut. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., eds. Krebs in Deutschland Berlin; 2015.
   Google Scholar
• Dörr M, Hölzel D, Schubert-Fritschle G, Engel J, Schlesinger-Raab A. Changes in prognostic and therapeutic parameters in prostate cancer from an epidemiological view over 20 years. Oncol Res Treat. 2015;38(1–2):8–14. doi:10.1159/00037171725633491
   PubMed Web of Science ®Google Scholar
• Winter A, Sirri E, Jansen L, et al. Comparison of prostate cancer survival in Germany and the United States: can differences be attributed to differences in stage distributions? BJU Int. 2017;119(4):550–559. doi: 10.1111/bju.135372016.
   Google Scholar
• Larrañaga N, Galceran J, Ardanaz E, et al. Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol. 2010;21(suppl3):iii83–iii89. doi:10.1093/annonc/mdq08720427365
   PubMedGoogle Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035. doi:10.1016/S0140-6736(14)60525-025108889
   PubMed Web of Science ®Google Scholar
• Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., eds. Krebs in Deutschland 2007/2008. Berlin; 2012.
   Google Scholar
• Eckersberger E, Finkelstein J, Sadri H, et al. Screening for prostate cancer: a review of the ERSPC and PLCO trials. Rev Urol. 2009;11(3):127.19918338
   PubMedGoogle Scholar
• Andriole GL, Crawford ED, Grubb III RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319. doi:10.1056/NEJMoa081069619297565
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–132. doi:10.1093/jnci/djr50022228146
   PubMed Web of Science ®Google Scholar
• de Koning HJ, Gulati R, Moss SM, et al. The efficacy of prostate-specific antigen screening: impact of key components in the ERSPC and PLCO trials. Cancer. 2018 Mar 15;124(6):1197–1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.
   Web of Science ®Google Scholar
• McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Reports. 2004;119(2):174–186. doi:10.1177/00333549041190021115192905
   PubMed Web of Science ®Google Scholar
• Winter A, Vohmann C, Wawroschek F, Kieschke J. Increase in uro-oncological health care needs due to demographic change: extrapolation of cancer incidence numbers through 2030 as a basis for directed regional planning. Urologe A. 2015;54(9):1261–1268. doi:10.1007/s00120-014-3698-725490922
   PubMedGoogle Scholar
• Meer S, Kollen BJ, Hirdes WH, et al. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate‐specific antigen (PSA) testing by Dutch general practitioners. BJU Int. 2013;112(1):26–31. doi:10.1111/bju.1202923465178
   PubMed Web of Science ®Google Scholar
• Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 3.1, 2014 AWMF Registernummer: 034/022OL. Available from: http://leitlinienprogrammonkologie.de/Leitlinien.7.0.html. Accessed October 15, 2014.
   Google Scholar
• Orom H, Biddle C, Underwood W 3rd, Nelson CJ, Homish DL. What is a “good” treatment decision? Decisional control, knowledge, treatment decision making, and quality of life in men with clinically localized prostate cancer. Med Decis Making. 2016;36(6):714–725. doi:10.1177/0272989X1663563326957566
   PubMed Web of Science ®Google Scholar
• Thomas R, Glasziou P, Rychetnik L, Mackenzie G, Gardiner R, Doust J. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men’s knowledge about and intentions to participate in PSA screening. BMJ Open. 2014;4(12):e005691. doi:10.1136/bmjopen-2014-005691
   PubMed Web of Science ®Google Scholar
• Pucheril D, Dalela D, Sammon J, et al. The influence of physician recommendation on prostate-specific antigen screening. Urol Oncol. 2015;33(10):424e421–427. doi:10.1016/j.urolonc.2015.06.013
   Web of Science ®Google Scholar
• Drummond FJ, Carsin AE, Sharp L, Comber H. Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners. BMC Fam Pract.  2009;10:3. doi: 10.1186/1471-2296-10-3.
   Web of Science ®Google Scholar
• Hjertholm P, Fenger-Gron M, Vestergaard M, et al. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study. Int J Cancer. 2015;136(2):435–442. doi:10.1002/ijc.2900824905402
   PubMed Web of Science ®Google Scholar
• Kötter T. “Family Practioners‘ counseling regarding PSA screening”: Practice recommendation of the German College of General Practitioners and Family Physicians (DEGAM). Z Allg Med. 2016;92(12):495-499.
   Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.
   Google Scholar
• Ballentine Carter H, Albertsen PC, Barry MJ, et al. Early detection of prostate Cancer: AUA Guideline. J Urol. 2013;190(2):419–426.
   Google Scholar
• (NCCN) NCCN. NCCN Clinical Practice Guidelines in Oncology – Prostate Cancer Early Detection, Version 2.2015. National Comprehensive Cancer Network (NCCN); 2015.
   Google Scholar
• Wolf AM, Wender RC, Etzioni RB, et al.American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98. doi: 10.3322/caac.20066.
   Google Scholar
• Moyer VA. U.S. Preventive services task force. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2012;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.
   Google Scholar
• Clements A, Watson E, Rai T, Bukach C, Shine B, Austoker J. The PSA testing dilemma: GPs’ reports of consultations with asymptomatic men: a qualitative study. BMC Fam Pract. 2007;8(1):35. doi:10.1186/1471-2296-8-3517593306
   PubMedGoogle Scholar
• Tun Firzara AM, Ng CJ. Knowledge and practice of prostate cancer screening among general practitioners in Malaysia: a cross-sectional study. BMJ Open. 2016;6:9. doi:10.1136/bmjopen-2016-011467
   Web of Science ®Google Scholar
• Zavaski ME, Meyer CP, Sammon JD, et al. Differences in prostate-specific antigen testing among urologists and primary care physicians following the 2012 USPSTF recommendations. JAMA Intern Med. 2016;176(4):546–547. doi:10.1001/jamainternmed.2015.790126857148
   PubMed Web of Science ®Google Scholar
• Sutton J, Melia J, Kirby M, Graffy J, Moss S. GPs views and understanding of PSA testing, screening and early detection; survey. Int J Clin Pract. 2016;70(5):389–395. doi:10.1111/ijcp.1279427121158
   PubMed Web of Science ®Google Scholar
• Birrenbach T, Kraehenmann S, Perrig M, Berendonk C, Huwendiek S. Physicians’ attitudes toward, use of, and perceived barriers to clinical guidelines: a survey among Swiss physicians. Adv Med Educ Pract. 2016;7:673–680. doi:10.2147/AMEP.S11514928008300
   PubMedGoogle Scholar
• Van der Meer S, Lowik SA, Hirdes WH, et al. Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review. BMC Fam Pract. 2012;13:100. doi:10.1186/1471-2296-13-5223052017
   PubMed Web of Science ®Google Scholar
• Bax C, Taverna G, Eusebio L, et al. Innovative diagnostic methods for early prostate cancer detection through urine analysis: a review. Cancers (Basel). 2018;10(4):E123. doi:10.3390/cancers1011040029670060
   PubMed Web of Science ®Google Scholar
• Tsoi T-H, Chan C-F, Chan W-L, et al. Urinary polyamines: a pilot study on their roles as prostate cancer detection biomarkers. PLoSONE. 2016;11:e0162217. doi:10.1371/journal.pone.0162217
   PubMed Web of Science ®Google Scholar
• Przydacz M, Golabek T, Sobanski JA, et al. Perception of lower urinary tract symptoms by psychiatrists in mentally affected patients. Psychiatr Pol. 2017;51(5):963–978. doi:10.12740/PP/7436529289974
   PubMed Web of Science ®Google Scholar
• Martini F, Lazzati A, Fritsch S, Liagre A, Iannelli A, Paolino L. General practitioners and bariatric surgery in france: are they ready to face the challenge? Obes Surg. 2018;28:1754–1759. doi:10.1007/s11695-017-3090-y29308535
   PubMedGoogle Scholar
• Starker A, Saß A-C. Inanspruchnahme von Krebsfrüherkennungsunter-suchungen. Bundesgesundheitsblatt - Gesundheitsforschung - Gesund-heitsschutz. 2013;56(5):858–867. doi:10.1007/s00103-012-1655-4
   PubMedGoogle Scholar
• Haider MR, Qureshi Z, Horner R, Bennett C. Factors predicting receipt of Prostate Specific Antigen (PSA) testing: evidence from the national ambulatory Medical Care Survey (Namcs) data. Value Health. 2015;18(3):A274. doi:10.1016/j.jval.2015.03.1598
   Web of Science ®Google Scholar
• Liu Y-M, Yang Y-HK, Hsieh C-R. Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: evidence from Taiwan. J Health Econ. 2009;28(2):341–349. doi:10.1016/j.jhealeco.2008.10.00919091433
   PubMed Web of Science ®Google Scholar
• Croxson B, Propper C, Perkins A. Do doctors respond to financial incentives? UK family doctors and the GP fundholder scheme. J Public Econ. 2001;79(2):375–398. doi:10.1016/S0047-2727(00)00074-8
   Web of Science ®Google Scholar